Myelodysplastic Syndromes
1,000
128
187
491
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
207 trials with published results (21%)
Research Maturity
491 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.3%
153 terminated out of 1000 trials
76.2%
-10.3% vs benchmark
8%
81 trials in Phase 3/4
42%
207 of 491 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 491 completed trials
Clinical Trials (1000)
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Mosaic Trial for Stem Cell Transplant Recipients
Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.